<DOC>
	<DOCNO>NCT00540930</DOCNO>
	<brief_summary>Uveal Melanoma common primary intraocular malignancy adulthood . Eye preserve treatment deliver equivalent life prognosis management small medium size uveal melanoma , compare enucleation . Plaque radiotherapy emerge common eye-preserving treatment current management uveal melanoma , complicate visual loss approximately 70 % patient 10 year follow-up . Strategies prevention early treatment radiation retinopathy/maculopathy need develop improve visual outcome follow plaque treatment . Ranibizumab ( Lucentis ) antigen bind fragment recombinant , humanize monoclonal antibody , inhibit activity vascular endothelial growth factor A , mediator development choroidal neovascularization . Lucentis commonly use eye eye condition age relate macular degeneration . This study investigate possible benefit Anti-VEGF therapy ( Lucentis ) reduce incidence radiation complication follow plaque radiation uveal melanoma .</brief_summary>
	<brief_title>Intravitreal Ranibizumab Prevention Radiation Maculopathy Following Plaque Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 18 year new diagnosis choroidal melanoma schedule plaque radiotherapy Wills Eye Health System Preexisting retinal disorder ( i.e . agerelated macular degeneration , diabetic maculopathy , retinal vascular occlusion , macular hole , surface wrinkle retinopathy ) prior retinal detachment medium opacity preclude accurate OCT image history glaucoma pregnancy age &lt; 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>